NCT05006508

Brief Summary

In this study participants will be randomized to use a digital lifestyle tool over three years or to a control group without access to the tool. The investigators will prospectively via clinical registries follow the incidence and development of type 2 diabetes over three years in those using the tool regularly and those in the control group.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
77,000

participants targeted

Target at P75+ for not_applicable

Timeline
7mo left

Started Aug 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress88%
Aug 2021Dec 2026

First Submitted

Initial submission to the registry

August 9, 2021

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 16, 2021

Completed
Same day until next milestone

Study Start

First participant enrolled

August 16, 2021

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 15, 2026

Expected
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Last Updated

August 14, 2025

Status Verified

July 1, 2025

Enrollment Period

5 years

First QC Date

August 9, 2021

Last Update Submit

August 10, 2025

Conditions

Outcome Measures

Primary Outcomes (4)

  • Incidence of type 2 diabetes

    Incidence of type 2 diabetes defined as random plasma glucose \>11.1 mmol/L or fasting glucose \>7.0 mmol/L or HbA1C ≥6.5% compared between participants regularly using the tool and on usual care.

    3 years

  • Change of long-term blood glucose concentration measured as glycated hemoglobin at end of follow-up

    Intraindividual change of long-term blood glucose concentration measured as glycated hemoglobin (HbA1c) at end of follow-up relative to baseline compared between participants regularly using the tool and on usual care.

    3 years

  • Prescription of anxiolytic medication

    Number of participants on prescription of anxiolytic medication between participants regularly using the tool and on usual care.

    3 years

  • Prescription of antidepessive medication

    Number of participants on prescription of antidepressive medication between participants regularly using the tool and on usual care.

    3 years

Secondary Outcomes (2)

  • Change of Anxiety estimated by General Anxiety Disorder 7-item scale

    1 year

  • Change of Patient Health Questionnaire 9-item scale

    1 year

Study Arms (2)

Usage of tool

EXPERIMENTAL

Participants get access to the tool and use it regularly

Behavioral: Lifestyle tool

Controls on usual care

NO INTERVENTION

Participants who get randomized to control cannot access the tool and get no further follow-up. Their development of type 2 diabetes or development of HbA1c is tracked via clinical registries.

Interventions

Lifestyle toolBEHAVIORAL

Regular use of the digital Lifestyle tool

Usage of tool

Eligibility Criteria

Age35 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • informed consent
  • Age above 35 years

You may not qualify if:

  • type 1 diabetes, MODY or secondary diabetes
  • conditions or treatments that in the judgement of the Investigator could affect the study evaluation
  • connection with the study team, funders, authorities, universities or other public or private bodies in such a way that specific interests in the study outcomes could be suspected.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Anders Rosengrentest

Malmo, Skåne County, 20502, Sweden

Location

Related Publications (1)

  • Dwibedi C, Abrahamsson B, Rosengren AH. Effect of Digital Lifestyle Management on Metabolic Control and Quality of Life in Patients with Well-Controlled Type 2 Diabetes. Diabetes Ther. 2022 Mar;13(3):423-439. doi: 10.1007/s13300-022-01214-2. Epub 2022 Feb 12.

Study Officials

  • Anders Rosengren, Prof

    Göteborg University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Participants get access to the tool or get assigned to a control group without access.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 9, 2021

First Posted

August 16, 2021

Study Start

August 16, 2021

Primary Completion (Estimated)

August 15, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

August 14, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will share

Individual participant data that underlie the results will be shared after deidentification.

Time Frame
Data will be available after publication.
Access Criteria
To researchers who provide a methodologically sound proposal in order to achieve the aims of that proposal. Proposals should be directed by email to internetverktyg@gu.se

Locations